Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current opinion in drug discovery & development

• Publication date

  2004-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 15338957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

  2004cited by this paper
• Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

  2003cited by this paper
• Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

  2003cited by this paper
• Farnesyl transferase inhibitors in clinical development

  2003cited by this paper
• Farnesyl transferase inhibitors in the treatment of breast cancer

  2003cited by this paper
• Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

  2003cited by this paper
• Farnesyl Transferase Inhibitors: Mechanism of Action, Translational Studies and Clinical Evaluation

  2003cited by this paper
• Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

  2003cited by this paper
• Farnesyltransferase inhibitors as radiation sensitizers.

  2002cited by this paper
• The Tyrosine Phosphatase PRL-1 Localizes to the Endoplasmic Reticulum and the Mitotic Spindle and Is Required for Normal Mitosis*

  2002cited by this paper
• Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

  2002cited by this paper
• Current progress on farnesyl protein transferase inhibitors.

  2002cited by this paper
• Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

  2002cited by this paper
• Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis.

  2002cited by this paper
• Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.

  2002cited by this paper
• The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

  2001cited by this paper
• Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.

  2001cited by this paper
• Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

  2001cited by this paper
• A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

  2001cited by this paper
• Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

  2001cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• Farnesyltransferase inhibitors: mechanism and applications

  2001cited by this paper
• Ras biochemistry and farnesyl transferase inhibitors: a literature survey

  2001cited by this paper
• Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice*

  2000cited by this paper
• Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

  2000cited by this paper
• The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

  2000cited by this paper
• A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

  2000cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999cited by this paper
• Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

  1999cited by this paper
• Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression*

  1999cited by this paper
• Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

  1998cited by this paper
• Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

  1998cited by this paper
• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  1998cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo *

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation*

  1997cited by this paper
• Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.

  1996cited by this paper
• Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases.

  1996cited by this paper
• Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

  1995cited by this paper
• Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

  1995cited by this paper
• Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

  1995cited by this paper
• A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

  1995cited by this paper
• Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

  1994cited by this paper
• Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

  1993cited by this paper
• Mammalian Ras interacts directly with the serine/threonine kinase Raf.

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro

  1993cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• Biochemistry of protein prenylation.

  1992cited by this paper
• p21ras is modified by a farnesyl isoprenoid.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• The ras gene family and human carcinogenesis.

  1988cited by this paper
• ras genes.

  1987cited by this paper

• Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling

  2024cites this paper
• Prenylated Proteins: Structural Diversity and Functions

  2023cites this paper
• Isoprenylcysteine Carboxyl Methyltransferase and Its Substrate Ras Are Critical Players Regulating TLR-Mediated Inflammatory Responses

  2020cites this paper
• Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery

  2018cites this paper
• GTP-Competitive Inhibitors of RAS Family Members

  2017cites this paper
• Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents

  2017cites this paper
• New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.

  2016cites this paper
• Validación de la enzima ICMT como una nueva diana terapéutica para el tratamiento del cáncer y la progeria

  2016cites this paper
• Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.

  2016cites this paper
• Protein prenylation: unique fats make their mark on biology

  2016cites this paper
• Pyrazole-based potent inhibitors of GGT1: Synthesis, biological evaluation, and molecular docking studies.

  2016cites this paper
• Studies on identification and in vivo function of novel drug target enzymes of Leishmania donovani using biomolecular approaches

  2016cites this paper
• Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells

  2015cites this paper
• Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets

  2014cites this paper
• Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

  2014cites this paper
• Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

  2014cites this paper
• Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach

  2013cites this paper
• Molecular determinants of cancer cell sensitivity and resistance towards the sesquiterpene farnesol.

  2013cites this paper
• Control of RhoA Methylation by Carboxylesterase I*

  2013cites this paper
• Advanced bladder cancer: new agents and new approaches. A review.

  2013cites this paper
• Computational enzymatic catalysis--clarifying enzymatic mechanisms with the help of computers.

  2012cites this paper
• Photochemical Modulation of Ras‐Mediated Signal Transduction Using Caged Farnesyltransferase Inhibitors: Activation by One‐ and Two‐Photon Excitation

  2012cites this paper
• Insights into the mechanistic dichotomy of the protein farnesyltransferase peptide substrates CVIM and CVLS.

  2012cites this paper
• Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.

  2011cites this paper
• Detection of farnesyltransferase interface hot spots through computational alanine scanning mutagenesis.

  2011cites this paper
• Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.

  2011cites this paper
• Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

  2011cites this paper
• Hutchinson-Gilford Progeria Syndrome with G608G LMNA Mutation

  2011cites this paper
• Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins.

  2011cites this paper
• Mechanistic Studies of Protein Lipidation: Yeast Palmitoyltransferase Akr1p and Protein Farnesyltransferase.

  2011cites this paper
• Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.

  2010cites this paper
• Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.

  2010cites this paper
• Simultaneous C- and N-Alkylation of 2-Oxo-4,6-diaryl-1,2,3,4-tetrahydropyridine-3-carbonitrile Under Solid–Liquid Phase-Transfer Conditions

  2010cites this paper
• Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.

  2010cites this paper
• Novel gene C17orf37 in Prostate Cancer Progression and Metastasis: A Prospective Biomarker

  2010cites this paper
• Anticancer activity of novel unnatural synthetic isoprenoids.

  2010cites this paper
• Discovery of C-imidazole azaheptapyridine FPT inhibitors.

  2010cites this paper
• TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation

  2010cites this paper
• Identification of autoantibody against fatty acid synthase in hepatocellular carcinoma mouse model and its application to diagnosis of HCC.

  2010cites this paper
• Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme.

  2009cites this paper
• Phosphatase of Regenerating Liver-3 Localizes to Cyto-Membrane and Is Required for B16F1 Melanoma Cell Metastasis In Vitro and In Vivo

  2009cites this paper
• Review Paper: The Role of Inflammation in Mouse Pulmonary Neoplasia

  2009cites this paper
• Role of Isoprenylcysteine Carboxylmethyltransferase-catalyzed Methylation in Rho Function and Migration*

  2009cites this paper
• Unraveling the Catalytic Pathway of Metalloenzyme Farnesyltransferase through QM/MM Computation.

  2009cites this paper
• Farnesyl protein transferase inhibitory components of Polygonum multiflorum

  2009cites this paper
• Protein Farnesyltransferase‐Catalyzed Isoprenoid Transfer to Peptide Depends on Lipid Size and Shape, not Hydrophobicity

  2008cites this paper
• A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L‐744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy

  2008cites this paper
• Molecular dynamics analysis of farnesyltransferase: A closer look into the amino acid behavior

  2008cites this paper
• Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells

  2008cites this paper
• Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation.

  2008cites this paper
• Towards Complete Sets of Farnesylated and Geranylgeranylated Proteins

  2007cites this paper
• Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues.

  2007cites this paper
• Theoretical studies on farnesyl transferase: Evidence for thioether product coordination to the active‐site zinc sphere

  2007cites this paper
• Ras as a therapeutic target in hematologic malignancies

  2007cites this paper
• Clinical activity of tipifarnib in hematologic malignancies

  2007cites this paper
• Transition state analysis of model and enzymatic prenylation reactions.

  2007cites this paper
• Quantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase.

  2007cites this paper
• New agents for treatment of advanced transitional cell carcinoma.

  2007cites this paper
• Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.

  2007cites this paper
• Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release.

  2007cites this paper
• Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.

  2007cites this paper
• Spermatinamine, the first natural product inhibitor of isoprenylcysteine carboxyl methyltransferase, a new cancer target.

  2007cites this paper
• Farnesyl Protein Transferase Inhibitory Components of Lithospermum erythrorhizon

  2007cites this paper
• Facile one-pot synthesis of N-difluoromethyl-2-pyridone derivatives.

  2006cites this paper
• Prevention of farnesylation of c‐Ha‐Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells

  2006cites this paper
• Emerging role of MAP kinase pathways as therapeutic targets in COPD

  2006cites this paper
• MicroRNAs as a potential magic bullet in cancer.

  2006cites this paper
• Human laminopathies: nuclei gone genetically awry

  2006cites this paper
• Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivo

  2006cites this paper
• A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity*

  2006cites this paper
• Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation Published, JLR Papers in Press, December 7, 2005.

  2006cites this paper
• Exploring structure-activity relationships of tricyclic farnesyltransferase inhibitors using ECLiPS libraries.

  2006cites this paper
• Measurement of the alpha-secondary kinetic isotope effect for the reaction catalyzed by mammalian protein farnesyltransferase.

  2006cites this paper
• Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

  2006cites this paper
• Theoretical studies on farnesyltransferase: The distances paradox explained

  2006cites this paper
• Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.

  2006cites this paper
• ISOPRENOID ANALOGS AS CHEMICAL GENETIC TOOLS TO PROVIDE INSIGHTS INTO FARNESYL TRANSFERASE TARGET SELECTION AND CELLULAR ACTIVITY

  2006influential citation
• ANTI-RAS STRATEGIES FOR CANCER TREATMENT

  2006cites this paper
• Effective tailor-made force field parameterization of the several Zn coordination environments in the puzzling FTase enzyme: opening the door to the full understanding of its elusive catalytic mechanism

  2006cites this paper
• Surfing the piperazine core of tricyclic farnesyltransferase inhibitors.

  2005cites this paper
• Cyclopentenediones, inhibitors of farnesyl protein transferase and anti-tumor compounds, isolated from the fruit of Lindera erythrocarpa Makino.

  2005cites this paper
• Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation.

  2005cites this paper
• Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

  2005cites this paper
• Isoprenylated proteins

  2005cites this paper
• Inhibidores de la HMG-CoA reductasa, angiogénesis y cáncer

  2005cites this paper
• Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.

  2005cites this paper
• Computational studies of the farnesyltransferase ternary complex part I: substrate binding.

  2005cites this paper
• Evaluation of geranylazide and farnesylazide diphosphate for incorporation of prenylazides into a CAAX box-containing peptide using protein farnesyltransferase.

  2005cites this paper
• Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.

  2005cites this paper
• Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

  2005cites this paper
• A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

  2005cites this paper
• A continuous fluorescent assay for protein prenyltransferases measuring diphosphate release.

  2005cites this paper
• Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways

  2005cites this paper
• Inhibition of the cell cycle with chemical inhibitors: a targeted approach.

  2005cites this paper
• Post-prenylation-processing enzymes as new targets in oncogenesis

  2005cites this paper
• Novel triazole based inhibitors of Ras farnesyl transferase.

  2005cites this paper
• Optimal management of the T1G3 bladder cancer.

  2005cites this paper
• Recent developments related to the EGFR as a target for cancer chemotherapy.

  2005cites this paper
• Refinement and prediction of protein prenylation motifs

  2005cites this paper